231 related articles for article (PubMed ID: 37847741)
1. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Targets in AML.
Ritz J
Blood Cancer Discov; 2023 Nov; 4(6):430-432. PubMed ID: 37847743
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan R; Olsson N; Wagar LE; Medeiros BC; Meyer E; Czerwinski D; Khodadoust MS; Zhang L; Schultz L; Davis MM; Elias JE; Levy R
PLoS One; 2019; 14(7):e0219547. PubMed ID: 31291378
[TBL] [Abstract][Full Text] [Related]
4. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
5. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
6. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
7. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
[TBL] [Abstract][Full Text] [Related]
8. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
9. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
10. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
11. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
[TBL] [Abstract][Full Text] [Related]
12. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
Dorrance AM; Neviani P; Ferenchak GJ; Huang X; Nicolet D; Maharry KS; Ozer HG; Hoellarbauer P; Khalife J; Hill EB; Yadav M; Bolon BN; Lee RJ; Lee LJ; Croce CM; Garzon R; Caligiuri MA; Bloomfield CD; Marcucci G
Leukemia; 2015 Nov; 29(11):2143-53. PubMed ID: 26055302
[TBL] [Abstract][Full Text] [Related]
13. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
14. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J
Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
[TBL] [Abstract][Full Text] [Related]
16. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
Mutis T; Schrama E; Melief CJ; Goulmy E
Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
[TBL] [Abstract][Full Text] [Related]
17. CD200 expression marks leukemia stem cells in human AML.
Ho JM; Dobson SM; Voisin V; McLeod J; Kennedy JA; Mitchell A; Jin L; Eppert K; Bader G; Minden MD; Dick JE; Wang JCY
Blood Adv; 2020 Nov; 4(21):5402-5413. PubMed ID: 33147339
[TBL] [Abstract][Full Text] [Related]
18. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
19. Can immunotherapy specifically target acute myeloid leukemic stem cells?
Snauwaert S; Vandekerckhove B; Kerre T
Oncoimmunology; 2013 Feb; 2(2):e22943. PubMed ID: 23526057
[TBL] [Abstract][Full Text] [Related]
20. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
Roerden M; Märklin M; Salih HR; Bethge WA; Klein R; Rammensee HG; Nelde A; Walz JS
Leuk Lymphoma; 2021 Aug; 62(8):1907-1919. PubMed ID: 33648413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
